ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca will invest more than $150 million to build a drug production facility in the Vorsino industrial park in Russia’s Kaluga region. The plant will focus on preparing and packaging final-dosage forms. Construction is to begin in April and be completed by 2013. In addition, AstraZeneca Russia and the Skolkovo innovation center have agreed to create drug development partnerships and new business models in Russia. Other major drug firms have made similar moves to set up production in Russia, including a $500 million investment by Novartis (C&EN, Jan. 3, page 9).
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter